GLASGOW, Scotland--(BUSINESS WIRE)--Dxcover Limited, a clinical-stage liquid biopsy company pioneering Multi-Omic Spectral Analysis for early detection of cancer, today announced that it has been awarded first prize for its poster focused on the detection of early-stage tumors across multiple cancers at the European Society for Medical Oncology (ESMO) Congress 2023 in the Innovative Diagnostic Tools category.
The poster titled “A Spectroscopic Liquid Biopsy for the Earlier Detection of Multiple Cancers” is based on a study which was recently published in the British Journal of Cancer. The study recruited 2,092 patients, including 1,592 cancer samples, to determine if the Dxcover Platform was able to differentiate cancer against non-cancer patients using Fourier Transform Infrared (FTIR) spectroscopy to analyze all macromolecules in patient serum and combined machine learning algorithms to build spectral profiles that detect breast, colorectal, kidney, lung, ovarian, pancreatic and prostate cancer. The cancer versus asymptomatic non-cancer classification detected 64% of stage I cancers when specificity was 99%, with an overall sensitivity of 56%. When tuned for higher sensitivity, this model identified 99% of stage I cancers with a specificity of 58%.
When examining cancer against all non-cancer (including symptomatic patients), the sensitivity-tuned model enabled 90% sensitivity with 61% specificity, with detection rates of 93% for stage I, 84% for stage II, 92% for stage III and 95% for stage IV.
“It is an honor to be recognized by such an esteemed organization as ESMO for Dxcover’s Multi-Omic Spectral Analysis. We are on a mission to detect cancer at its earliest stages to increase the likelihood of effective treatment options for patients,” said Prof. Matthew Baker, co-founder and Chief Technology Officer at Dxcover. “It is so rewarding to be part of this robust scientific community and we look forward to developing partnerships that enable us to bring Dxcover’s unique cancer screening method to those who will benefit from it most.”
Early symptoms of many cancers can be non-specific and easily overlooked by patients and doctors. Delayed diagnosis can permit cancer metastasis and lead to poorer prognosis and increased treatment costs as therapies are typically less effective for late-stage disease. An early detection platform that is capable of detecting multiple cancer types and the precursors of cancer could rule out non-cancer patients and help prioritize at-risk patients for rapid diagnostic investigation. Dxcover has also completed a retrospective colorectal study indicating enhanced capability to detect advanced adenomas, the precursor of colorectal cancer, and will be starting a major prospective collection of samples later this year.
About Dxcover Limited
Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered Multi-Omic Spectral Analysis for the early detection of cancer by infrared spectroscopy and has generated compelling clinical data with high accuracy detection of Stage I and II cancers and adenomas.
Dxcover is based in Scotland, United Kingdom and is expanding its network in Europe and the USA.
For further information go to https://www.dxcover.com/science